Xencor (XNCR) Receivables (2013 - 2026)
Xencor (XNCR) reported Receivables of $12.0 million for Q1 2026, down 68.24% year-over-year from $37.8 million in Q1 2025, and down 59.04% quarter-over-quarter from $29.3 million in Q4 2025.
Xencor (XNCR) Receivables (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Receivables data on file, last reported at $12.0 million in Q1 2026.
- Receivables for Q1 2026 came in at $12.0 million, down 68.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (down 68.24% YoY), and the FY2025 annual result was $29.3 million, down 55.97% from the prior year.
- Receivables slipped to $12.0 million in Q1 2026 per XNCR's latest filing, from $29.3 million in the prior quarter.
- Over five years, Receivables peaked at $93.2 million in Q1 2022 and troughed at $2.2 million in Q3 2023.
- A 5-year average of $34.7 million and a median of $29.3 million in 2025 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2024: Receivables tumbled 95.1% in 2023, then soared 1076.0% in 2024.
- A 5-year view of Receivables shows it stood at $30.3 million in 2022, then dropped by 14.05% to $26.0 million in 2023, then jumped by 155.57% to $66.5 million in 2024, then sank by 55.97% to $29.3 million in 2025, then tumbled by 59.04% to $12.0 million in 2026.
- Business Quant data shows XNCR's Receivables at $12.0 million in Q1 2026, $29.3 million in Q4 2025, and $21.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 12.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | 29.30 Mn |
| Sep 30, 2025 | 21.81 Mn |
| Jun 30, 2025 | 47.55 Mn |
| Mar 31, 2025 | 37.79 Mn |
| Dec 31, 2024 | 66.55 Mn |
| Sep 30, 2024 | 25.87 Mn |
| Jun 30, 2024 | 35.92 Mn |
| Mar 31, 2024 | 22.18 Mn |
| Dec 31, 2023 | 26.04 Mn |
| Sep 30, 2023 | 2.20 Mn |
| Jun 30, 2023 | 20.02 Mn |
| Mar 31, 2023 | 19.86 Mn |
| Dec 31, 2022 | 30.30 Mn |
| Sep 30, 2022 | 44.88 Mn |
| Jun 30, 2022 | 54.28 Mn |
| Mar 31, 2022 | 93.20 Mn |
| Dec 31, 2021 | 67.18 Mn |
| Sep 30, 2021 | 20.55 Mn |
| Jun 30, 2021 | 15.33 Mn |